← Back to Search

DHRT Training Devices for Central Venous Catheter Placement Skills

N/A
Recruiting
Led By Scarlett R Miller, Ph.D.
Research Sponsored by Milton S. Hershey Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient undergoing central venous catheterization
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (pre-intervention), post-intervention
Awards & highlights

Study Summary

This trial will test whether two devices used to train medical residents improve the residents' ability to place central venous catheters, and whether this results in fewer complications for patients.

Who is the study for?
This trial is for medical residents learning to insert central venous catheters (CVCs) and patients undergoing CVC procedures. Residents must be in their first year at Hershey Medical Center or Cedars-Sinai Medical Center, and patients must be scheduled for a CVC insertion.Check my eligibility
What is being tested?
The study tests two training devices: the Dynamic Haptic Robotic Trainer (DHRT) and an advanced version, DHRT+. It measures how well these tools help residents learn to perform CVC insertions compared to current training methods.See study design
What are the potential side effects?
There are no direct side effects from using the DHRT or DHRT+ as they are non-invasive training tools. However, there's always a risk of infection or complications associated with actual CVC insertion procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am getting a central venous catheter placed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-intervention), post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-intervention), post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Central Line Related Complications due to new Resident Central Line Training Procedures
Change in Central Line Related Infections due to new Resident Central Line Training Procedures

Trial Design

2Treatment groups
Experimental Treatment
Group I: Residents to receive Dynamic Haptic Robotic TrainingExperimental Treatment1 Intervention
Group II: Residents to receive Advanced Dynamic Haptic Robotic TrainingExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Milton S. Hershey Medical CenterLead Sponsor
494 Previous Clinical Trials
2,798,217 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,836 Previous Clinical Trials
47,850,232 Total Patients Enrolled
Scarlett R Miller, Ph.D.Principal InvestigatorPenn State University

Media Library

Advanced Dynamic Haptic Robotic Trainer (DHRT+) Clinical Trial Eligibility Overview. Trial Name: NCT04541446 — N/A
Central Line Bloodstream Infection Research Study Groups: Residents to receive Advanced Dynamic Haptic Robotic Training, Residents to receive Dynamic Haptic Robotic Training
Central Line Bloodstream Infection Clinical Trial 2023: Advanced Dynamic Haptic Robotic Trainer (DHRT+) Highlights & Side Effects. Trial Name: NCT04541446 — N/A
Advanced Dynamic Haptic Robotic Trainer (DHRT+) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04541446 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment phase of this trial open to participants yet?

"From the records maintained on clinicaltrials.gov, this research project is still open to potential participants. The trial was created in August of 2020 and had its most recent update fifteen days ago in June 2022."

Answered by AI

To what extent is this investigation being implemented?

"Affirmative. The clinicaltrial.gov website affirms that this medical endeavour is still recruiting patients, and was initiated on August 19th 2020 with the last edit being done June 15th 2022. 625 people are needed to be enrolled across 2 different sites for full participation in this trial."

Answered by AI
~27 spots leftby Jul 2024